Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Rush Street Interactive Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Rush Street Interactive Inc trades at $33.62 (market cap $3.45B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.3× Rush Street Interactive Inc's market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | RSI | |
|---|---|---|
Market Cap | $8.04B | $3.45B |
Sector | Health | Technology |
52-Week High | $339.75 | $34.18 |
52-Week Low | $241.71 | $14.51 |
Enterprise Value | $7.85B | $3.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
RSI stock trades at $34.18, up 2.34% today, with a bullish technical signal from moving averages and strong institutional support. Recent Q1 2026 earnings beat expectations with EPS of $0.14 versus $0.12 expected, while revenue grew to $1.13B in 2025. The company expanded into Alberta with BetRivers launch, enhancing its online gaming footprint.
Outlook remains positive with 76.9% analyst buy ratings and a consensus price target of $29.44, though high valuation multiples (P/E 98.56) and overbought RSI levels near 77.56 pose near-term risks. Key catalysts include Q2 2026 earnings on July 29, 2026, and execution of the $100M share repurchase program.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
